There are two main reasons for poor compliance with schizo meds: the dissociative nature of the disease itself, and the common side effects. The latter should be much less with a muscarinic modulator, if it's well tolerated. Our phase 1 went well, and hopefully acceptable GI tolerability continued in the 2a (and shows efficacy of course). We'll be finding out in a couple months, looking forward to it.
In two weeks we'll be getting 2-73's full AD OLE results, which are valuable in understanding the long term AD efficacy.
Market Data 
Markets 
AI
